🔎 Trials Near Me

Home › Arteriovenous Fistula › NCT06807099

WRAP North America

RecruitingObservational study

Prospective, Multicenter, Observational Study to Evaluate the Merit WRAPSODY® Cell Impermeable Endoprosthesis for Treatment of Stenosis or Occlusion Within the Dialysis Outflow Circuit (WRAP North America)

Who can join

Ages 18 and older · All sexes

Full eligibility criteria
Inclusion Criteria:

1. Subject provides written informed consent for study participation.
2. Subject is male or female, with an age ≥ 18 years at date of enrollment.
3. Subject is willing to comply with site standard of care procedures and follow-up visit schedules over 36 months.
4. Subject is undergoing chronic hemodialysis with the hemodialysis access the intervention will be performed upon.
5. The dialysis access is considered mature and has been used to deliver hemodialysis treatments for at least one session.
6. Subject has stenosis or occlusion within the dialysis outflow circuit and is treated with WRAPSODY CIE in accordance with device instructions for use.

Exclusion Criteria:

1. Subject has a planned surgical revision of access site.
2. Subject has a known or suspected infection of the hemodialysis access site, systemic infection and/or septicemia.
3. Subject has an uncorrectable coagulation disorder.
4. Known hypersensitivity to nickel or titanium.
5. Subject's hemodialysis access is anticipated to be abandoned within 6 months.
6. Subject is scheduled for kidney transplant or peritoneal dialysis within the next 6 months post-procedure.
7. Full expansion of a PTA balloon cannot be achieved during predilatation.
8. Device would be placed in the Superior Vena Cava
9. Any inflow or outflow lesion that could jeopardize patency access long-term beyond the target treatment area.

About the study

The goal of this observational study is to investigate the safety and efficacy of the WRAPSODY CIE in a real-world North American population. Participants treated with the WRAPSODY CIE device in accordance with the device instructions for use will be followed in accordance with standard of care up to 3-years post-procedure.

What is being tested

Sponsor: Merit Medical Systems, Inc. · Participants: 250 · Started: Jul 31, 2025

Contact the study team

Official record on ClinicalTrials.gov — NCT06807099

Locations in the U.S.

AlabamaTrinity Research Group, Dothan
ArizonaAKDHC Phoenix Surgery Center, Phoenix
CaliforniaApex Research of Riverside, Riverside
FloridaAmerican Access Care of Jacksonville, Jacksonville
Sarasota Memorial Research Institute, Sarasota
KentuckyUniversity of Kentucky, Lexington
Rhode IslandAmerican Access Care of Rhode Island, Providence
South CarolinaMedical University of South Carolina, Charleston
Medical University of South Carolina, Orangeburg
Spartanburg Medical System, Spartanburg
TexasTexas Research Institute, Fort Worth
Humble Vascular Surgical Center, Humble
VirginiaSentara Vascular Specialists, Virginia Beach

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.